Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,

Slides:



Advertisements
Similar presentations
The Statistical Consensus of Non-Inferiority Clinical Trail for NDA in CHINA XIA J.L., PhD. Prof of Biostatistics of FMMU On behalf of CCTS Working Group.
Advertisements

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Use of Data Monitoring Committees (DMC) in Device Trials: An FDA Division of Cardiovascular Devices (DCD) Perspective Bram Zuckerman MD, FACC
Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD * No official support.
Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.
Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute.
OPC Koustenis, Breiter. General Comments Surrogate for Control Group Benchmark for Minimally Acceptable Values Not a Control Group Driven by Historical.
1 Other Issues for Statisticians in Medical Devices Gregory Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health,
Roseann White Clin/Reg Felllow Abbott Vascular – Cardiac Therapies
1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Susan Boynton, VP, Global Regulatory Affairs, Shire
Strengthening the Medical Device Clinical Trial Enterprise
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Clinical Trials Hanyan Yang
INCLUSION/EXCLUSION CRITERIA 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion.
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Points for Discussion Panelists: Drs.Iwasaki, Takahashi, Wood.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
1 FDA/CDRH Office of In Vitro Diagnostic Devices The Pre-IDE Process Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD.
Challenges of Non-Inferiority Trial Designs R. Sridhara, Ph.D.
New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.
Development and the Role of Meta- analysis on the Topic of Inflammation Donald S. Likosky, Ph.D.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.
© Guidant 2005 Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician.
Statistical Methods in the Evaluation of Red Blood Cell Products (In vivo study) Jessica Kim, Ph.D. Mathematical Statistician FDA/CBER/OBE/DB Blood Products.
بسم الله الرحمن الرحیم.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
European Patients’ Academy on Therapeutic Innovation Clinical Trial Designs.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
Clinical trials for medical devices: FDA and the IDE process
Rachel Neubrander, PhD Division of Cardiovascular Devices
My Experiences as an FDA Statistician
FDA Division of Cardiovascular Devices
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
CLINICAL PROTOCOL DEVELOPMENT
FDA’s IDE Decisions and Communications
Balancing Pre and Postmarket Requirements Different Scenarios
Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Statistical Approaches to Support Device Innovation- FDA View
Donald E. Cutlip, MD Beth Israel Deaconess Medical Center
Deputy Director, Division of Biostatistics No Conflict of Interest
Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Regulatory Considerations for Coronary Drug Coated Balloons – FDA View
Erica Takai, PhD for Andrew Farb, M.D.
Critical Reading of Clinical Study Results
FDA/INDUSTRY STATISTICS WORKSHOP: Washington, D. C. Sept
Ethical Principles of Research
Speeding access to therapies
New FDA Guidance on Early Alzheimer’s Disease
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Regulatory Perspective of the Use of EHRs in RCTs
Aparna Raychaudhuri, Ph. D
Presentation transcript:

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic, Inc.

Background If clinical data are needed, FDA and industry should consider alternatives to randomized, controlled clinical trials when potential bias associated with alternative controls can be addressed. Source: The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry, Oct. 4, 2002, CDRH ODE and CBER.

Randomized or Non-randomized Considerations Randomization helps minimize bias. But, what if patients cant be blinded? –Consider amount of bias (e.g., death vs. QOL). Can evaluators be blinded? Is a control group necessary for a reasonable evaluation? Magnitude of change from existing predicate device(s).

Types of Non-randomized Trials Trials with historical controls Trials using objective performance criteria (OPC) Registry trials

Definition Objective Performance Criteria (OPC) are performance criteria based on broad sets of data from historical databases (e.g., literature or registries) that are generally recognized as acceptable values. These criteria may be used for surrogate or clinical endpoints in demonstrating the safety or effectiveness of a device. Source: The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry, Oct. 4, 2002, CDRH ODE and CBER.

Historical control? Are historical data available? Are the populations comparable? –For the primary endpoint, not necessarily demographics.

OPC How to determine OPC? –Past, similar, approved devices. –Use the point estimate or that studys OPC? –Statisticians job? How do we balance statistical need / sample size / reasonable OPC? –E.g., if we expect the failure rate to be 5%, should OPC be 10% (n=239) or 15% (n=76)?